Literature DB >> 17198779

Activation of protein C and hemodynamic recovery after coronary artery bypass surgery.

Peter Raivio1, Jose A Fernández, Anne Kuitunen, John H Griffin, Riitta Lassila, Jari Petäjä.   

Abstract

OBJECTIVES: Activated protein C is a physiologic anticoagulant that is activated by thrombin and upregulated during coronary artery bypass grafting. We studied the balance between thrombin generation and activated protein C levels during coronary artery bypass grafting and hypothesized that protein C activation during reperfusion is associated with hemodynamic recovery or postoperative myocardial damage.
METHODS: One hundred patients undergoing elective on-pump coronary artery bypass grafting were prospectively studied. Activated protein C, protein C, prothrombin fragment F1+2 (a marker of thrombin generation), and D-dimer (a marker of fibrinolysis) levels were measured preoperatively and at 7 time points during cardiopulmonary bypass and reperfusion and postoperatively. Hemodynamic parameters were measured serially. Cardiac biomarkers (mass of the Mb fraction of creatine kinase and troponin T) were measured postoperatively.
RESULTS: Reperfusion induced a significant increase in thrombin generation. Activated protein C levels peaked after heparin neutralization, when they increased more than 3-fold. Activated protein C levels correlated with F1+2 and D-dimer levels during cardiopulmonary bypass and reperfusion. Even though this correlation peaked during early reperfusion (r = 0.55, P < .001), the ratio of activated protein C to F1+2 decreased during surgical intervention and early reperfusion by 70% from the preoperative level, indicating a marked delay in protein C activation in relation to thrombin generation. Patients in the highest quintile of activated protein C levels during this period had a higher postoperative cardiac index (mean, 3.1 vs 2.5 L x min(-1) x m(-2); P < .05) and lower systemic vascular resistance (mean, 2137 vs 2429 dyne x s x cm(-5) x m(-2); P < .05). Conversely, levels of preoperative activated protein C and activated protein C measured after heparin neutralization were associated with unfavorable hemodynamic recovery postoperatively. Activated protein C or protein C levels were not associated with increased postoperative cardiac biomarkers.
CONCLUSIONS: Reperfusion caused significant thrombin generation that was followed by activation of protein C. The balance of activated protein C with thrombin is associated dynamically with postoperative hemodynamic recovery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198779     DOI: 10.1016/j.jtcvs.2006.10.003

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass.

Authors:  Satoru Ogawa; James E Richardson; Tetsuro Sakai; Masahiro Ide; Kenichi A Tanaka
Journal:  J Anesth       Date:  2011-10-19       Impact factor: 2.078

2.  Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism.

Authors:  John-Bjarne Hansen; José A Fernández; Knut H Borch; John H Griffin; Jan H Brox; Sigrid K Braekkan
Journal:  Thromb Res       Date:  2011-07-20       Impact factor: 3.944

3.  Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study.

Authors:  Beata Przybyla; Anne Pinomäki; Jari Petäjä; Lotta Joutsi-Korhonen; Karin Strandberg; Andreas Hillarp; Ann-Kristin Öhlin; Tapani Ruutu; Liisa Volin; Riitta Lassila
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

4.  Discrepant fibrinolytic response in plasma and whole blood during experimental endotoxemia in healthy volunteers.

Authors:  Sisse R Ostrowski; Ronan M G Berg; Nis A Windeløv; Martin A S Meyer; Ronni R Plovsing; Kirsten Møller; Pär I Johansson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.